On ECHEMI
Home > Drugs > Hunan Wzt Pharmaceutical Co., Ltd.
Hunan Wzt Pharmaceutical Co., Ltd.
  • Founded in:

    2000-02-29
  • Country:

    China China
  • Address:

    No. 219, Biquantan Road, Tianyi Economic Development Zone, Xiangtan, Hunan Province
  • Tax NO.:

    91430300740629832Q
  • Registered Funds:

    8.08 million yuan
  • Website:

  • Email:

Related Drugs
Myo-aminoglycan for injection
This product contains a variety of cardiovascular active substances, the main components of which include atrial peptides, calcitonin gene-related peptides and nucleotides (nucleosides) such as adenosine triphosphate (adenosine), in addition to more than 20 amino acids and their metabolic intermediates.
Name Description Content CAS NO. Registered Holders
atriopeptin II

98084-69-6 0
calcitonin gene related peptide

0
ADENOSINE 5'-TRIPHOSPHATASE

9000-83-3 0
Adenosine

58-61-7 14
Polycresol sulfonate solution
Polycresol sulfonate.
Name Description Content CAS NO. Registered Holders
Policresulen

No specific pharmacological information is provided

More

No specific pharmacological information is provided

9011-02-3 10
Oxymatrine injection
The main ingredient of this product is matrine, also known as oxymatrine.
Name Description Content CAS NO. Registered Holders
Ammothamnine

It has a significant effect on increasing the number of peripheral blood leukocytes in normal rabbits. The peak of the leukocyte count occurs on the 4th day after the first administration, which is 72% higher than before the administration, which is better than the leukocyte-raising drug shark liver alcohol. It has a significant effect on increasing leukocytes in rabbits induced by cobalt 60-gamma rays and deep X-ray irradiation. It also has a preventive effect on leukopenia when administered two days before irradiation. It can also prevent leukopenia in mice caused by mitomycin C. It has a synergistic inhibitory effect on solid Ehrlich carcinoma when used in combination with cyclophosphamide, and the toxicity of leukopenia caused by cyclophosphamide is significantly reduced.

More

It has a significant effect on increasing the number of peripheral blood leukocytes in normal rabbits. The peak of the leukocyte count occurs on the 4th day after the first administration, which is 72% higher than before the administration, which is better than the leukocyte-raising drug shark liver alcohol. It has a significant effect on increasing leukocytes in rabbits induced by cobalt 60-gamma rays and deep X-ray irradiation. It also has a preventive effect on leukopenia when administered two days before irradiation. It can also prevent leukopenia in mice caused by mitomycin C. It has a synergistic inhibitory effect on solid Ehrlich carcinoma when used in combination with cyclophosphamide, and the toxicity of leukopenia caused by cyclophosphamide is significantly reduced.

16837-52-8 11
Dihydroergoline Mesylate Injection
Dihydroergoceptin mesylate is composed of equal proportions of dihydroergocornine mesylate, dihydroergocryptine mesylate (there are two isomers, dihydro-α-ergocryptine mesylate and dihydro-β-ergocryptine mesylate, in a ratio of 2:1) and dihydroergoline mesylate.
Name Description Content CAS NO. Registered Holders
Dihydroergotoxine mesylate

It changes the signal transmission of the central nervous system, has an stimulatory effect on dopamine receptors and 5-hydroxytryptamine receptors, has a blocking effect on α-adrenergic receptors, improves damaged brain metabolic function, shortens cerebral circulation time, improves symptoms of intellectual decline, stabilizes cerebral vascular tension, and prevents migraines.

More

It changes the signal transmission of the central nervous system, has an stimulatory effect on dopamine receptors and 5-hydroxytryptamine receptors, has a blocking effect on α-adrenergic receptors, improves damaged brain metabolic function, shortens cerebral circulation time, improves symptoms of intellectual decline, stabilizes cerebral vascular tension, and prevents migraines.

8067-24-1 13
Dihydroergocornine mesylate

As a component of dihydroergotamine mesylate, they work together to improve brain metabolic function and stabilize cerebral vascular tone.

More

As a component of dihydroergotamine mesylate, they work together to improve brain metabolic function and stabilize cerebral vascular tone.

0
Dihydroergocryptine mesylate

As a component of dihydroergotamine mesylate, they work together to improve brain metabolic function and stabilize cerebral vascular tone.

More

As a component of dihydroergotamine mesylate, they work together to improve brain metabolic function and stabilize cerebral vascular tone.

0
Dihydro-α-ergocryptine mesylate

As one of the isomers of dihydroergocryptine mesylate, it is involved in improving brain metabolic function and stabilizing cerebral vascular tone.

More

As one of the isomers of dihydroergocryptine mesylate, it is involved in improving brain metabolic function and stabilizing cerebral vascular tone.

0
Dihydro-β-ergocryptine mesylate

As one of the isomers of dihydroergocryptine mesylate, it is involved in improving brain metabolic function and stabilizing cerebral vascular tone.

More

As one of the isomers of dihydroergocryptine mesylate, it is involved in improving brain metabolic function and stabilizing cerebral vascular tone.

0
Dihydroergoline mesylate

As a component of dihydroergotamine mesylate, they work together to improve brain metabolic function and stabilize cerebral vascular tone.

More

As a component of dihydroergotamine mesylate, they work together to improve brain metabolic function and stabilize cerebral vascular tone.

0
Tetracaine Hydrochloride for Injection
The main ingredient of this product is tetracaine hydrochloride, and its chemical name is 4-(butylamino)-benzoic acid-2-(dimethylamino)ethyl ester hydrochloride.
Name Description Content CAS NO. Registered Holders
Tetracaine hydrochloride

After entering the blood, most of it binds to plasma proteins and accumulates in tissues, with the largest accumulation in skeletal muscle. When the concentration in plasma decreases, it is released again. Most of it is hydrolyzed and converted by plasma cholinesterase, metabolized by the liver into p-aminobenzoic acid and dimethylaminoethanol, and then degraded or combined and excreted in the urine.

More

After entering the blood, most of it binds to plasma proteins and accumulates in tissues, with the largest accumulation in skeletal muscle. When the concentration in plasma decreases, it is released again. Most of it is hydrolyzed and converted by plasma cholinesterase, metabolized by the liver into p-aminobenzoic acid and dimethylaminoethanol, and then degraded or combined and excreted in the urine.

136-47-0 16
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.